

## Chronic cardiotoxicity testing in human-induced pluripotent stem cell-derived cardiomyocytes using impedance and multielectrode array

**Commonly used acronym:** Chronic cardiotoxicity testing in hiPSC-CMs using impedance and MEA

Created on: 12-12-2024 - Last modified on: 13-12-2024

### Organisation

**Name of the organisation** Janssen Pharma of JNJ

**Department** Research and Development

**Country** Belgium

**Geographical Area** Flemish Region

### SCOPE OF THE METHOD

<b>The Method relates to</b>	Human health
<b>The Method is situated in</b>	Translational - Applied Research, Other: Safety pharmacology/toxicology testing
<b>Type of method</b>	In vitro - Ex vivo
<b>Specify the type of cells/tissues/organs</b>	human induced pluripotent stem cell-derived cardiomyocytes

### DESCRIPTION

#### Method keywords

in vitro assay  
multi electrode array  
predictivity  
hiPSC-CMs

#### Scientific area keywords

drug-induced cardiotoxicity  
arrhythmias  
Cardiac electrophysiology  
Drug safety

#### Method description

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were seeded in 48-well multielectrode array (MEA) plates and were treated with four doses of reference compounds (covering and exceeding clinical free plasma peak concentrations) and MEA recordings were conducted for 4 days. Functional-electrophysiological (field-potentials) and viability (impedance) parameters were recorded with a MEA machine.

#### Lab equipment

Multielectrode array

### Method status

Internally validated

Published in peer reviewed journal

## PROS, CONS & FUTURE POTENTIAL

### Advantages

Human-based model, repeated and non-invasive recordings, chronic

### Challenges

Cell maturation

## REFERENCES, ASSOCIATED DOCUMENTS AND OTHER INFORMATION

### References

Altrocchi C, Van Ammel K, Steemans M, Kreir M, Tekle F, Teisman A, Gallacher DJ and Lu HR (2023) Evaluation of chronic drug-induced electrophysiological and cytotoxic effects using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Front. Pharmacol. 14:1229960. doi: 10.3389/fphar.2023.1229960

Coordinated by



Financed by



Vlaanderen  
verbeelding werkt

